SCHEMBL882969

SCHEMBL882969

CC(=O)c1nccc(C)n1

nearest known ligand 0.45

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
SORD Q00796 3/20 0.45
ALOX15 P16050 1/20 0.44
KMT2A Q03164 3/20 0.43
ALDH1A1 P00352 1/20 0.38
NPC1 O15118 3/20 0.37
RAB9A P51151 3/20 0.37
CYP1A2 P05177 1/20 0.37
CYP2C9 P11712 1/20 0.37
CYP2C19 P33261 1/20 0.37
KMO O15229 2/20 0.37
FASN P49327 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
SMN1; SMN2 Q16637 3/20 0.36
POLB P06746 2/20 0.36
NPSR1 Q6W5P4 1/20 0.35
KDM4E B2RXH2 1/20 0.35
MEN1 O00255 1/20 0.35
PRNP P04156 1/20 0.35
GAA P10253 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1578222 0.83 KMO (0.51) ALOX15KMT2AKMO
SCHEMBL2465653 0.81 KMT2A (0.50) ALOX15KMT2ANPC1RAB9ACYP2C9
SCHEMBL23747677 0.78 ALOX15 (0.37) SORDALOX15KMT2ANPC1RAB9A
SCHEMBL1256533 0.78 ALDH1A1 (0.47) SORDKMT2AALDH1A1NPC1RAB9A
SCHEMBL30210828 0.78 ALOX15 (0.41) ALOX15KMT2ANPC1RAB9AFASN
SCHEMBL38660994 0.78 ALOX15 (0.41) ALOX15KMT2AALDH1A1CYP1A2CYP2C19
SCHEMBL1670929 0.78 ALOX15 (0.41) ALOX15KMT2AALDH1A1CYP1A2CYP2C19
SCHEMBL17819430 0.78 ALOX15 (0.45) ALOX15KMT2AALDH1A1NPC1RAB9A
SCHEMBL7077382 0.78 KMT2A (0.43) ALOX15KMT2AALDH1A1NPC1RAB9A
SCHEMBL16421042 0.77 SORD (0.44) SORDKMT2AALDH1A1CYP1A2CYP2C19

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230116972-A1 CD38 MODULATORS AND METHODS OF USE THEREOF CYTOKINETICS, INC. 2023-04-20 US disclosed
EP-3042900-B1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF FUJIFILM CORP (JP) 2020-09-23 EP disclosed
US-9586951-B2 Morpholine derivative or salt thereof FUJIFILM CORPORATION (JP) 2017-03-07 US disclosed
US-9586951-B2 Morpholine derivative or salt thereof FUJIFILM CORPORATION (JP) 2017-03-07 US disclosed
US-9586951-B2 Morpholine derivative or salt thereof FUJIFILM CORPORATION (JP) 2017-03-07 US disclosed
EP-3042900-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF Fujifilm Corporation (JP) 2016-07-13 EP disclosed
US-20160184306-A1 Novel Pyrimidinyl-DiazoSpiro Compounds Convergence Pharmaceuticals Limited (GB) 2016-06-30 US disclosed
US-20160168139-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2016-06-16 US disclosed
US-20160168139-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2016-06-16 US disclosed
US-20160168139-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF FUJIFILM CORPORATION (JP) 2016-06-16 US disclosed
US-9309254-B2 Pyrimidinyl-diazospiro compounds Convergence Pharmaceuticals Limited (GB) 2016-04-12 US disclosed
US-20150119404-A1 NOVEL COMPOUNDS CONVERGANCE PHARMACEUTICALS LIMITED (GB) 2015-04-30 US disclosed
US-20140309244-A1 NOVEL MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2014-10-16 US disclosed
US-20140309244-A1 NOVEL MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2014-10-16 US disclosed
US-20140309244-A1 NOVEL MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2014-10-16 US disclosed
EP-2641901-A1 Novel microbiocides Syngenta Participations AG. (CH) 2013-09-25 EP disclosed
WO-2012038521-A1 NOVEL MICROBIOCIDES SYNGENTA PARTICIPATIONS AG (CH) 2012-03-29 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20160184306-A1 Novel Pyrimidinyl-DiazoSpiro Compounds TRPV1, KCNJ2, KCNN2 SORD 1370/4885ALOX15 1919/4885KMT2A 3766/4885
US-20140309244-A1 NOVEL MICROBIOCIDES MSR1, C3AR1, CD209 SORD 1598/4885ALOX15 365/4885KMT2A 3934/4885
US-20160168139-A1 NOVEL MORPHOLINE DERIVATIVE OR SALT THEREOF PRMT7, RBBP7, RER1 SORD 2965/4885ALOX15 4709/4885KMT2A 1128/4885
US-20230116972-A1 CD38 MODULATORS AND METHODS OF USE THEREOF CD38, CXCR4, FCGRT SORD 3038/4885ALOX15 1323/4885KMT2A 2789/4885
US-20150119404-A1 NOVEL COMPOUNDS KCNJ2, KCNN3, KCNN2 SORD 930/4885ALOX15 2477/4885KMT2A 3551/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.